Table 3. Detection of HCV in Two Sequential Paired Plasma and PBMC.

		First Sample Collections				Second Sample Collections
		HCV RNA + Strand				HCV RNA + Strand
		Plasma					Plasma		PBMC
Patient Age/Sex	Genotype	250 μl	~5 ml	PBMC PHA-Treated	HCV RNA-Strand PBMC	Time from First Collection (Years)	250 μl	~5 ml	PHA-Treated	CS-Treated	HCV RNA-Strand PBMC
4-6/M	1b	NEG	NEG	NEG	NT	5.2	NEG	POS	POS	NT	NEG
7-73/F	NT	NEG	NEG	NEG	NT	5.5	NEG	NEG	NEG	NEG	NT
10-70/M	1a	NEG	NEG	POS	NEG	6.5	NEG	NEG	NEG	NEG	NT
14-47/F	2a	NEG	POS	POS	NEG	4.5	NEG	NEG	NEG	POS	POS
15-46/F	3a	POS	NT	POS	POS	5.1	NEG	POS	NEG	POS	POS
16-52/F	1b	NEG	NEG	POS	NEG	7.2	POS	NT	NEG	NEG	NT
17-47/M	NT	NEG	NEG	NEG	NT	6.3	NEG	NEG	NEG	NEG	NT
20-49/F	1b	POS	NT	NEG	NT	6.3	NEG	POS	POS	NT	POS
24-53/M	1b	NEG	POS	NA	NA	6.7	NEG	NEG	NEG	POS	POS
Mean or Number From Total		2/9	2/7	4/8	1/4	5/9	1/9	3/8	2/9	3/7	4/5

PBMC, peripheral blood mononuclear cells; HCV RNA+, HCV RNA positive strand; HCV RNA-, HCV RNA negative strand; PHA, phytohemagglutinin; C5, immune cell stimulating cocktail (see Materials and Methods); POS, positive; NEG, negative; NT, not tested; NA, not available.